Novo, however, vastly underestimated the appetite for its new weight-loss jab. Mr Doustdar says it planned for demand to be three times that of Saxenda, an older and less-effective weight-loss drug.

Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...

Up to 3,000 people will take part ...

Claudia Oshry got real about her postpartum body. Oshry, 31, took to Instagram on Monday, December 15, to share that she’s ...

Eli Lilly’s weight loss drugs have delivered blockbuster sales in recent quarters. The company is a leader in this market ...

A notable finding is that audiences are split on whether they see more pharma ads in 2025 compared to 2024. Nearly half of ...

Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as new therapies expand global market leadership.

Bynes has been vocal about her weight-loss journey, which began in June with the trendy GLP-1 agonist drug Ozempic so she ...

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3% in the afternoon session after the ...

Novo Nordisk finds itself navigating significant operational and market headwinds. The company is intensely focused on maintaining its leadership in the obes ...

GLP-1s for weight loss may not affect the risk of obesity-related cancers either way, an analysis of the existing evidence ...